Autolus Therapeutics (AUTL) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026Commercial performance and adoption
AUCATZYL (obe-cel) generated $74M in its first launch year; second-year revenue reached $113M in the first 9 months, including $41M in Q3. FY guidance rose from $120M-$135M to $140M-$150M; revenue is now expected at $150M or higher.
The U.S. launch has reached 90 centers and the U.K. 20; second-year revenue is expected to increase ~100% YoY, supported by physician experience and peer communication.
U.S. coverage exceeds 80% of patients; expansion will target geographic gaps, referring centers with patient flow, and facilities where CAR T-trained physicians establish practices.
ROCCA real-world data covering about two-thirds of first-year patients showed no high-grade cytokine release syndrome, 3% higher-grade transient neurological toxicity, and clinical activity above 90%.
Adoption is expected to build gradually as physicians gain confidence and use obe-cel across more eligible patients; conference presentations and peer exchange are key potential catalysts.
Manufacturing and margins
Q3 gross margin was 57%; year-to-date gross margin was 44%. Production is expected to double versus last year with fewer manufacturing operators and staff.
Gross margin is targeted at 65%-70% by 2028, with the ALL business expected to be cash-flow positive in 2028.
Margin improvement is expected from higher production volume spreading fixed costs and continued operational efficiency work across manufacturing steps.
Label and market expansion
The pediatric pivotal study is expected to complete enrollment by year-end or very early next year; data are expected at ASH next year, with an sBLA filing ready around that time.
Investigator-led frontline studies use two induction chemotherapy cycles followed by obe-cel consolidation, aiming to shorten treatment from 18-36 months to 4-6 months; first MD Anderson data are expected late next year.
Discussions are underway with cooperative groups and the NCI on a potential randomized, label-enabling frontline study.
The U.S. adult relapsed/refractory ALL peak-sales opportunity is estimated at $500M; expansion across ages and treatment lines could exceed $1B.
The U.K. launched in early 2026 after NICE assessment and routine commissioning; sales are expected to reach roughly 10% of U.S. sales. European launches may begin around 2028 if reimbursement and cost of goods support attractive economics; Europe potential was estimated at 20%-25%.
Latest events from Autolus Therapeutics
- AUCATZYL growth and expanding obe-cel trials broaden the commercial opportunity.AUTL
Corporate presentation - AUCATZYL revenue rose 95%, gross margin reached 57%, and FY2026 guidance is at least $150M.AUTL
Q3 2026 - IPO-funded cash supports expanding T-cell trials, but losses and clinical risks remain significant.AUTL
Q4 2018 - A £113.5m loss funded a growing T-cell pipeline, with COVID-19 clouding timelines.AUTL
Q4 2019 - Cash runway extended to May 2023 as clinical development drives continued losses.AUTL
Q4 2021 - Licensing growth and a £316.3m cash balance offset a wider loss, with funding needed beyond June 2024.AUTL
Q4 2022 - Obe-cel advanced toward a 2024 decision, backed by encouraging data and $600M in February proceeds.AUTL
Q4 2023 - Resale registration for 3.5M ADSs linked to a warrant, supporting T cell therapy expansion.AUTL
Registration filing - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTL
Q2 2026